Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Berg

Showing results (501-510 of 633) with videos related to

Pageof 64
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis DToni Herta, Christopher Dietz-Fricke, Münevver Demir, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2023
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug ClassesMarion G Peters, Man-Fung Yuen, Norah Terrault, et al.
Journal of Hepatology|June 28, 2011
The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutationJacob Nattermann, Jörg Timm, Hans Dieter Nischalke, et al.
Gastroenterology|March 23, 2011
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis CJordi Bruix, Thierry Poynard, Massimo Colombo, et al.
The New England Journal of Medicine|April 15, 2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosisFred Poordad, Christophe Hezode, Roger Trinh, et al.
Hepatology (Baltimore, Md.)|May 13, 2011
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological responseRoeland Zoutendijk, Jurriën G P Reijnders, Ashley Brown, et al.
Nature Genetics|September 15, 2009
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyVijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel, et al.
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC - A Substudy From the SORAMIC TrialKerstin Schütte, Juozas Kupčinskas, Egidijus Morkunas, et al.
Plos One|December 11, 2020
Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver diseaseAli Bayoumi, Ismail Jalil, Mayada Metwally, et al.
Plos One|July 19, 2012
A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis CChristian M Lange, Stephanie Bibert, Zoltan Kutalik, et al.
Pageof 64

Showing results (501-510 of 633) with videos related to

Sort By:
Pageof 64
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis DToni Herta, Christopher Dietz-Fricke, Münevver Demir, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2023
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug ClassesMarion G Peters, Man-Fung Yuen, Norah Terrault, et al.
Journal of Hepatology|June 28, 2011
The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutationJacob Nattermann, Jörg Timm, Hans Dieter Nischalke, et al.
Gastroenterology|March 23, 2011
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis CJordi Bruix, Thierry Poynard, Massimo Colombo, et al.
The New England Journal of Medicine|April 15, 2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosisFred Poordad, Christophe Hezode, Roger Trinh, et al.
Hepatology (Baltimore, Md.)|May 13, 2011
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological responseRoeland Zoutendijk, Jurriën G P Reijnders, Ashley Brown, et al.
Nature Genetics|September 15, 2009
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyVijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel, et al.
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC - A Substudy From the SORAMIC TrialKerstin Schütte, Juozas Kupčinskas, Egidijus Morkunas, et al.
Plos One|December 11, 2020
Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver diseaseAli Bayoumi, Ismail Jalil, Mayada Metwally, et al.
Plos One|July 19, 2012
A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis CChristian M Lange, Stephanie Bibert, Zoltan Kutalik, et al.
Pageof 64